Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0407)
Drug Name
Dacomitinib
Synonyms
Dacomitinib; Dacomitinib (PF299804, PF299); Dacomitinib [USAN:INN]; J-500784; PF 00299804-03; PF-00299804; PF-00299804-03; PF299804; dacomitinibum; pf00299804; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide; (2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide; (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide; 1110813-31-4; 2XJX250C20; C24H25ClFN5O2; PF299; UNII-2XJX250C20
Indication Lung cancer [ICD11: 2C25] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 469.9 Topological Polar Surface Area 79.4
Heavy Atom Count 33 Rotatable Bond Count 7
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 7
Cross-matching ID
PubChem CID
11511120
PubChem SID
16613030 ; 23640600 ; 74609599 ; 135263265 ; 135626635 ; 136340260 ; 136349571 ; 136367702 ; 140977763 ; 152159560 ; 152258509 ; 160647344 ; 162011542 ; 162038136 ; 162205175 ; 164041746 ; 172918917 ; 174505192 ; 174526192 ; 178103994 ; 185997026 ; 189622863 ; 194690240 ; 198956821 ; 223382341 ; 223705276 ; 252109876 ; 252216044 ; 252451737 ; 252451797
ChEBI ID
CHEBI:132268
CAS Number
1110813-31-4
TTD Drug ID
D06XXH
Formula
C24H25ClFN5O2
Canonical SMILES
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4
InChI
1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+
InChIKey
LVXJQMNHJWSHET-AATRIKPKSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
PF-05199265 DM001864
136045759
Oxidation - O-Demethylation 1 [2] , [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000716 Dacomitinib PF-05199265 Oxidation - O-Demethylation CYP2C9 ... [2], [3]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
References
1 Dacomitinib was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
3 Dacomitinib: an investigational drug for the treatment of glioblastoma Expert Opin Investig Drugs. 2018 Oct;27(10):823-829. doi: 10.1080/13543784.2018.1528225.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.